Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma

Blood ◽  
2013 ◽  
Vol 121 (17) ◽  
pp. 3431-3433 ◽  
Author(s):  
Jing Ouyang ◽  
Annette Plütschow ◽  
Elke Pogge von Strandmann ◽  
Katrin S. Reiners ◽  
Sabine Ponader ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Clinical Features ◽  
Serum Levels ◽  
Tumor Burden ◽  
Clinical Parameters ◽  
Classical Hodgkin Lymphoma ◽  
Key Points ◽  
Normal Controls

Key Points Serum levels of galectin-1 are significantly higher in patients with cHL than in normal controls. Galectin-1 serum levels are associated with clinical parameters of tumor burden in patients with cHL.

scholarly journals Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

Blood ◽  
2018 ◽  
Vol 131 (22) ◽  
pp. 2413-2425 ◽  
Author(s):  
Valeria Spina ◽  
Alessio Bruscaggin ◽  
Annarosa Cuccaro ◽  
Maurizio Martini ◽  
Martina Di Trani ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Residual Disease ◽  
Clonal Evolution ◽  
Circulating Tumor Dna ◽  
Classical Hodgkin Lymphoma ◽  
Key Points ◽  
Tumor Dna

Key Points ctDNA is as an easily accessible source of tumor DNA for cHL genotyping. ctDNA is a radiation-free tool to track residual disease in cHL.

scholarly journals Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

Blood ◽  
2018 ◽  
Vol 131 (22) ◽  
pp. 2454-2465 ◽  
Author(s):  
Enrico Tiacci ◽  
Erik Ladewig ◽  
Gianluca Schiavoni ◽  
Alex Penson ◽  
Elisabetta Fortini ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Hodgkin Lymphoma ◽  
Classical Hodgkin Lymphoma ◽  
Key Points ◽  
Stat Pathway

Key Points Identification of genes frequently mutated in cHL, fostering tumor growth in a manner amenable to pharmacological targeting. Mutated genes include the almost ubiquitous targeting of JAK-STAT pathway members, as well as GNA13, XPO1, and ITPKB.

Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis

Blood ◽  
2014 ◽  
Vol 123 (23) ◽  
pp. 3567-3573 ◽  
Author(s):  
Katharine H. Xing ◽  
Joseph M. Connors ◽  
Anky Lai ◽  
Mubarak Al-Mansour ◽  
Laurie H. Sehn ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Aggressive Lymphoma ◽  
Matched Pair ◽  
Outcome Analysis ◽  
Advanced Stage ◽  
Classical Hodgkin Lymphoma ◽  
Increased Risk ◽  
Key Points

Key PointsTTP is inferior in patients with advanced-stage NLPHL compared with CHL. Spleen involvement is associated with an increased risk of secondary aggressive lymphoma in patients treated with ABVD-like chemotherapy.

scholarly journals Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis

2017 ◽  
Vol 26 (7) ◽  
pp. 1114-1123 ◽  
Author(s):  
Lynn I. Levin ◽  
Elizabeth C. Breen ◽  
Brenda M. Birmann ◽  
Julie L. Batista ◽  
Larry I. Magpantay ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Elevated Serum ◽  
Serum Levels ◽  
Classical Hodgkin Lymphoma

scholarly journals Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival

Blood ◽  
2013 ◽  
Vol 121 (10) ◽  
pp. 1795-1804 ◽  
Author(s):  
Girish Venkataraman ◽  
Joo Y. Song ◽  
Alexandar Tzankov ◽  
Stephan Dirnhofer ◽  
Georg Heinze ◽  
...  
Keyword(s):  
Overall Survival ◽  
T Cell ◽  
Hodgkin Lymphoma ◽  
Antigen Expression ◽  
Classical Hodgkin Lymphoma ◽  
Event Free Survival ◽  
Free Survival ◽  
Cell Antigen ◽  
Nodular Sclerosis ◽  
Key Points

Key Points Cases of cHL may express TCA on the neoplastic cells. TCA-cHL have nodular sclerosis histology and lack T-cell genotype, with worse outcome compared with TCA-negative cHLs.

scholarly journals Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries

Blood ◽  
2015 ◽  
Vol 126 (17) ◽  
pp. 1990-1995 ◽  
Author(s):  
Elham Kharazmi ◽  
Mahdi Fallah ◽  
Eero Pukkala ◽  
Jörgen H. Olsen ◽  
Laufey Tryggvadottir ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Familial Risk ◽  
Nordic Countries ◽  
Age At Diagnosis ◽  
Classical Hodgkin Lymphoma ◽  
Risk Estimates ◽  
Key Points ◽  
Joint Study ◽  
Age And Sex

Key Points We provide clinically relevant familial risk estimates for classical HL patients by relationship, histology, age at diagnosis, and sex.

scholarly journals Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma

Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 128
Author(s):  
Raphael Lievin ◽  
Houria Hendel-Chavez ◽  
Aliou Baldé ◽  
Rémi Lancar ◽  
Michèle Algarte-Génin ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Activation ◽  
Cell Subset ◽  
Serum Levels ◽  
Classical Hodgkin Lymphoma ◽  
Cell Counts ◽  
Cytokine Levels ◽  
B Cell Subsets

Classical Hodgkin Lymphoma incidence increases in HIV-1-infected patients (HIV-cHL). HIV infection is associated with higher B-cell activation. Here, in 38 HIV-cHL patients from the French cohort ANRS-CO16 Lymphovir, we examined longitudinally over 24 months the serum levels of the B-cell activating cytokines IL10, IL6, and BAFF, and blood distribution of B-cell subsets. Fourteen HIV-cHL patients were also compared to matched HIV-infected controls without cHL. IL10, IL6, and BAFF levels were higher in HIV-cHL patients than in controls (p < 0.0001, p = 0.002, and p < 0.0001, respectively). Cytokine levels increased in patients with advanced-stage lymphoma compared to those with limited-stage (p = 0.002, p = 0.03, and p = 0.01, respectively). Cytokine levels significantly decreased following HIV-cHL diagnosis and treatment. Blood counts of whole B-cells were similar in HIV-cHL patients and controls, but the distribution of B-cell subsets was different with higher ratios of naive B-cells over memory B-cells in HIV-cHL patients. Blood accumulation of naive B-cells was more marked in patients with advanced cHL stages (p = 0.06). During the follow-up, total B-cell counts increased (p < 0.0001), and the proportion of naive B-cells increased further (p = 0.04). Together the results suggest that in HIV-infected patients, cHL is associated with a particular B-cell-related environment that includes increased production of B-cell-activating cytokines and altered peripheral distribution of B-cell subsets. This B-cell-related environment may fuel the process of tumorigenesis.

scholarly journals Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells

Blood ◽  
2013 ◽  
Vol 122 (16) ◽  
pp. 2856-2863 ◽  
Author(s):  
Paul Greaves ◽  
Andrew Clear ◽  
Andrew Owen ◽  
Sameena Iqbal ◽  
Abigail Lee ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
T Helper Cells ◽  
Cytokine Secretion ◽  
Classical Hodgkin Lymphoma ◽  
T Helper ◽  
Activation Markers ◽  
Helper Cells ◽  
Key Points ◽  
Proliferation In Vitro

Key Points Hodgkin lymphoma microenvironment T-helper cells express TH1/activation markers and lack TH2/immunosuppression markers. These cells are functional, retaining the capacity for cytokine secretion and proliferation in vitro.

Serum TARC Levels Correspond with Tumor Load and Response to Chemotherapy in Classical Hodgkin Lymphoma Patients.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3663-3663
Author(s):  
Arjan Diepstra ◽  
Anne Marijn van der Graaf ◽  
Hans JTWM Vos ◽  
Lydia Visser ◽  
Anke Van Den Berg ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Metabolic Response ◽  
Serum Levels ◽  
Tumor Burden ◽  
Response To Therapy ◽  
Pet Scan ◽  
Stage I ◽  
Healthy Controls ◽  
Advanced Stage ◽  
Classical Hodgkin Lymphoma

Abstract Abstract 3663 Poster Board III-599 Introduction Thymus and Activation Related Chemokine (TARC) is produced in high amounts by Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL). It attracts CCR4 positive Th2 and Treg cells, which are typically present in large numbers in the reactive infiltrate in cHL. TARC can be measured in the serum of cHL patients and is usually elevated in the presence of active disease, as compared to healthy controls. Higher levels are observed in advanced stage disease, compared to stage I disease. The goal of the current study was to correlate TARC serum levels to metabolic response to therapy as measured by FDG-PET scanning. Patients and methods Newly diagnosed cHL patients treated in our hospital were asked to participate. Serum samples were taken before the start of treatment, at the time of the mid treatment PET scan (after 2 cycles of ABVD for stage I and II, or mid BEACOPP or ABVD treatment for stage III and IV disease) and at the time of the PET scan after completion of chemotherapy. TARC serum levels were measured by ELISA and TARC immunohistochemistry was done on primary involved lymph node tissue. Results A total of 59 cHL patients, median age 40 (range 16-80) and 49% male participated. Eight patients had stage I, 26 stage II, 14 stage III and 10 stage IV disease. The known association of high pretreatment TARC levels with advanced stage was also significantly present in our data, supporting the hypothesis that serum TARC levels reflect tumor burden. Moreover, in stage I and II patients, bulky disease (27%) was associated with a significant higher TARC level, lending further support to this hypothesis. Compared to pretreatment values, TARC levels had decreased significantly at mid treatment and treatment completion to the range of healthy controls. Only in stage I there was no significant difference between pretreatment and mid or after treatment samples (see figure), probably due to the relatively large number of patients without elevated TARC before the start of therapy. In patients with a positive PET scan at mid treatment (26%), there was a trend for a higher TARC level (P=0.08) compared to PET negative patients. After completion of chemotherapy PET positivity (19%) was significantly associated with a higher TARC level. Three patients had a relapse and at that time TARC levels had clearly increased in comparison to the levels after treatment. Conclusions serum TARC levels are associated with tumor burden and metabolic response to therapy as measured by FDG-PET scan. Measurement of serum TARC levels is a potential tool to evaluate the response to therapy and to be used in follow up after completion of chemotherapy. Inclusion of more patients is necessary to further assess the clinical value of TARC serum levels and is ongoing. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document